

## Additional medical benefit drugs to have site-of-care requirements for BCN commercial members starting Sept. 1

Starting Sept. 1, 2022, the following drugs will have site-of-care requirements for Blue Care Network group and individual commercial members:

- Bavencio® (avelumab), HCPCS code J9023
- Imfinzi® (durvalumab), HCPCS code J9173
- Keytruda® (pembrolizumab), HCPCS code J9271
- Libtayo® (cemiplimab-rwic), HCPCS code J9119
- Opdivo® (nivolumab), HCPCS code J9299
- Tecentriq® (atezolizumab), HCPCS code J9022
- Yervoy® (ipilimumab), HCPCS code J9228

When the site-of-care requirements go into effect, these drugs may be covered only when administered at the following sites of care:

- Doctor's or other health care provider's office
- Home infusion therapy provider
- Ambulatory infusion center

These drugs already require prior authorization through AIM Specialty Health®. The new site-of-care requirements are in addition to the current prior authorization requirements.

This change doesn't apply to Blue Cross Blue Shield of Michigan commercial members or to our Medicare Advantage (BCN Advantage<sup>SM</sup> and Medicare Plus Blue<sup>SM</sup>) members.

### How the site-of-care requirements will be phased in

The site-of-care requirements will apply as follows for infusions involving any of the drugs listed above:

- **For courses of therapy starting on or after Sept. 1, 2022:** These infusions may not be covered at outpatient hospital facilities starting Sept. 1, 2022.
- **For courses of therapy in progress as of Sept. 1, 2022:**
  - These infusions may not be covered at outpatient hospital facilities starting Dec. 1, 2022.
  - If you choose to continue the member's treatment in an outpatient hospital facility, you'll need to obtain prior authorization from AIM before Dec. 1 to continue the infusions at an outpatient hospital facility.

### What to do for members currently receiving these drugs

- For BCN commercial members who currently receive these drugs at an outpatient hospital facility, you should do the following:
  - Check the list of [In-network home infusion therapy providers and ambulatory infusion centers](#) at which the member may be able to continue their infusion therapy.
  - Discuss with the member how to facilitate moving their infusions to one of the allowed sites of care.
- For BCN commercial members who currently receive these drugs at a doctor's office, at home or in an ambulatory infusion center:
  - Make sure that you or the center bills infusions as a doctor's office, home infusion therapy provider or an ambulatory infusion center. Some offices and clinics are considered part of an outpatient hospital and bill as a hospital.
  - If you or the center bills as a hospital, you must obtain prior authorization for the member to continue receiving infusions there or the services won't be covered. If the prior authorization request isn't approved, the member will need to switch to a different infusion therapy provider for the services to be covered.

### How we'll help

For members who need to transition to a new infusion location, we'll work with you and the member to facilitate the transition. We'll notify members and do the following:

- Encourage them to talk to you before changing their infusion location
- Let them know that this location change does not affect the treatment you're providing

### List of requirements

For a list of requirements related to drugs covered under the medical benefit that require authorization, refer to the [Blue Cross and BCN utilization management medical drug list](#) for Blue Cross and BCN commercial members. We'll update this list prior to Sept. 1.

You can access this list and other information about requesting prior authorization from AIM on BCN's [Medical Benefit Drugs page](#) on our [ereferrals.bcbsm.com](#) website.

AIM Specialty Health is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.

CareCentrix is an independent company that manages the in-state, independent home infusion services and ambulatory infusion center provider network for Blue Cross Blue Shield of Michigan and Blue Care Network members who have commercial plans.